Please assess the completion status of the following clinical trial:

Trial Title: Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients who completed 8-week short-term treatment study, 13267A (NCT01140906), for Major Depressive Episode immediately prior to enrolment in this extension study~Exclusion Criteria:~* Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV TR)~* Female patients of childbearing potential who are not using effective contraception~* Use of any psychoactive medication~* The patient, in the investigator's clinical judgment, has a significant risk of suicide.~Other protocol-defined inclusion and exclusion criteria applied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).